Imaging brain gene expression profiles by antipsychotics: Region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1516-1529

  De Bartolomeis, Andrea ^a   Marmo, Federica ^a   Buonaguro, Elisabetta Filomena ^a   Rossi, Rodolfo ^a   Tomasetti, Carmine ^a   Iasevoli, Felice ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atypical antipsychotics; Dopamine; Gene expression; Homer; Psychosis; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; DNA; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; SULFUR 35;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN; BRAIN REGION; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENE SEQUENCE; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; ISOTOPE LABELING; LIMBIC SYSTEM; MALE; MOLECULAR IMAGING; NERVE CELL PLASTICITY; NEUROPHARMACOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RAT; TISSUE SPECIFICITY;

ATYPICAL ANTIPSYCHOTICS; DOPAMINE; GENE EXPRESSION; HOMER; PSYCHOSIS; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION PROFILING; GENES, IMMEDIATE-EARLY; HALOPERIDOL; LIMBIC SYSTEM; MALE; ORGAN SPECIFICITY; POST-SYNAPTIC DENSITY; RATS; SULPIRIDE;

EID: 84886769539     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.11.014     Document Type: Article

References (51)

1. Ambesi-Impiombato A., D'Urso G., Muscettola G., de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Res. Protoc. 2003, 11:189-196.
2. Ambesi-Impiombato A., Panariello F., Dell'aversano C., Tomasetti C., Muscettola G., deBartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse 2007, 61:429-439.
3. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 1998, 18:5301-5310.
4. Boyer P., Lecrubier Y., Stalla-Bourdillon A., Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999, 39:25-32.
5. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R., Flanagan R.J., Ell P.J., Pilowsky L.S. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am. J. Psychiatry 2003, 160:1413-1420.
6. de Bartolomeis A., Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacol. Bull. 2003, 37:51-83.
7. de Bartolomeis, A., Tomasetti, C., 2012. Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. Mol. Neurobiol. 46, 275-296.
8. Featherstone R.E., McDonald R.J. Dorsal striatum and stimulus-response learning: lesions of the dorsolateral, but not dorsomedial, striatum impair acquisition of a stimulus-response-based instrumental discrimination task, while sparing conditioned place preference learning. Neuroscience 2004, 124:23-31.
9. Fumagalli F., Caffino L., Racagni G., Riva M.A. Repeated stress prevents cocaine-induced activation of BDNF signaling in rat prefrontal cortex. Eur. Neuropsychopharmacol. 2009, 19:402-408.
10. Fumagalli F., Frasca A., Racagni G., Riva M.A. Antipsychotic drugs modulate Arc expression in the rat brain. Eur. Neuropsychopharmacol. 2009, 19:109-115.
11. Graybiel A.M. Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 2008, 31:359-387.
12. Grunder G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8:197-202.
13. Iasevoli F., Ambesi-Impiombato A., Fiore G., Panariello F., Muscettola G., de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. J. Psychopharmacol. 2011, 25:875-887.
14. Iasevoli F., Cicale M., Abbott L.C., de Bartolomeis A. Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: a model of spontaneously occurring motor disturbances. Neurosci. Lett. 2011, 503:176-180.
15. Iasevoli F., Tomasetti C., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:813-821.
16. Iasevoli F., Tomasetti C., de Bartolomeis A. Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochem. Res. 2012, 38:1-22.
17. Iasevoli F., Tomasetti C., Marmo F., Bravi D., Arnt J., de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berlin) 2010, 212:329-344.
18. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
19. Kim D.H., Maneen M.J., Stahl S.M. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009, 6:78-85.
20. Lecrubier Y. Is amisulpride an 'atypical' atypical antipsychotic agent?. Int. Clin. Psychopharmacol. 2000, 15(Suppl. 4):S21-26.
21. Leucht S., Pitschel-Walz G., Engel R.R., Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002, 159:180-190.
22. Meisenzahl E.M., Schmitt G., Grunder G., Dresel S., Frodl T., la Fougere C., Scheuerecker J., Schwarz M., Boerner R., Stauss J., Hahn K., Moller H.J. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008, 41:169-175.
23. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain Res. 2008, 172:177-197.
24. Mo Y.Q., Jin X.L., Chen Y.T., Jin G.Z., Shi W.X. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology 2005, 30:261-267.
25. Moller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251:217-224.
26. Moller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1101-1111.
27. Moller H.J. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:190-201.
28. Moller H.J., Boyer P., Fleurot O., Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berlin) 1997, 132:396-401.
29. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr. Res. 2008, 105:224-235.
30. Nichols C.D., Garcia E.E., Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res. Mol. Brain Res. 2003, 111:182-188.
31. Nichols C.D., Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 2002, 26:634-642.
32. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011, 17:97-103.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic, San Diego London. Compact 3rd ed.
34. Perrault G., Depoortere R., Morel E., Sanger D.J., Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280:73-82.
35. Polese D., de Serpis A.A., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of d-cycloserine. Neuropsychopharmacology 2002, 27:906-913.
36. Ramaekers J.G., Louwerens J.W., Muntjewerff N.D., Milius H., de Bie A., Rosenzweig P., Patat A., O'Hanlon J.F. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J. Clin. Psychopharmacol. 1999, 19:209-221.
37. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280:83-97.
38. Shirvalkar P., Seth M., Schiff N.D., Herrera D.G. Cognitive enhancement with central thalamic electrical stimulation. Proc. Natl. Acad. Sci. USA 2006, 103:17007-17012.
39. Smith M.J., Wang L., Cronenwett W., Mamah D., Barch D.M., Csernansky J.G. Thalamic morphology in schizophrenia and schizoaffective disorder. J. Psychiatr. Res. 2011, 45:378-385.
40. Spellmann I., Rujescu D., Musil R., Mayr A., Giegling I., Genius J., Zill P., Dehning S., Opgen-Rhein M., Cerovecki A., Hartmann A.M., Schafer M., Bondy B., Muller N., Moller H.J., Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J. Psychiatr. Res. 2011, 45:234-241.
41. Steiner H., Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J. Neurosci. 1993, 13:5066-5081.
42. Stone J.M., Bressan R.A., Erlandsson K., Ell P.J., Pilowsky L.S. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology (Berlin) 2005, 180:664-669.
43. Stone J.M., Davis J.M., Leucht S., Pilowsky L.S. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs-an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr. Bull. 2009, 35:789-797.
44. Szumlinski K.K., Kalivas P.W., Worley P.F. Homer proteins: implications for neuropsychiatric disorders. Curr. Opin. Neurobiol. 2006, 16:251-257.
45. Tomasetti C., Dell'Aversano C., Iasevoli F., de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience 2007, 150:144-158.
46. Tomasetti C., Dell'Aversano C., Iasevoli F., Marmo F., de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:184-197.
47. Trichard C., Paillere-Martinot M.L., Attar-Levy D., Recassens C., Monnet F., Martinot J.L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry 1998, 155:505-508.
48. Vernaleken I., Siessmeier T., Buchholz H.G., Hartter S., Hiemke C., Stoeter P., Rosch F., Bartenstein P., Grunder G. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int. J. Neuropsychopharmacol. 2004, 7:421-430.
49. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
50. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur. J. Neurosci. 2003, 17:1053-1066.
51. Yamada H., Kuroki T., Nakahara T., Hashimoto K., Tsutsumi T., Hirano M., Maeda H. The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens. Brain Res. 2007, 1131:88-96.